INCY
Price
$83.63
Change
+$0.49 (+0.59%)
Updated
Sep 16, 12:25 PM (EDT)
Capitalization
16.24B
49 days until earnings call
JAZZ
Price
$126.01
Change
+$0.79 (+0.63%)
Updated
Sep 16, 12:57 PM (EDT)
Capitalization
7.6B
50 days until earnings call
Interact to see
Advertisement

INCY vs JAZZ

Header iconINCY vs JAZZ Comparison
Open Charts INCY vs JAZZBanner chart's image
Incyte
Price$83.63
Change+$0.49 (+0.59%)
Volume$813
Capitalization16.24B
Jazz Pharmaceuticals
Price$126.01
Change+$0.79 (+0.63%)
Volume$501
Capitalization7.6B
INCY vs JAZZ Comparison Chart in %
Loading...
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INCY vs. JAZZ commentary
Sep 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and JAZZ is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 16, 2025
Stock price -- (INCY: $83.14 vs. JAZZ: $125.22)
Brand notoriety: INCY: Notable vs. JAZZ: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 100% vs. JAZZ: 76%
Market capitalization -- INCY: $16.24B vs. JAZZ: $7.6B
INCY [@Biotechnology] is valued at $16.24B. JAZZ’s [@Biotechnology] market capitalization is $7.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 0 FA rating(s) are green whileJAZZ’s FA Score has 0 green FA rating(s).

  • INCY’s FA Score: 0 green, 5 red.
  • JAZZ’s FA Score: 0 green, 5 red.
According to our system of comparison, INCY is a better buy in the long-term than JAZZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 3 TA indicator(s) are bullish while JAZZ’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 3 bullish, 5 bearish.
  • JAZZ’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than INCY.

Price Growth

INCY (@Biotechnology) experienced а -3.95% price change this week, while JAZZ (@Biotechnology) price change was -3.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.30%. For the same industry, the average monthly price growth was +6.86%, and the average quarterly price growth was +34.07%.

Reported Earning Dates

INCY is expected to report earnings on Nov 04, 2025.

JAZZ is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+3.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INCY($16.2B) has a higher market cap than JAZZ($7.6B). INCY has higher P/E ratio than JAZZ: INCY (19.65) vs JAZZ (15.38). INCY YTD gains are higher at: 20.371 vs. JAZZ (1.681). INCY has higher annual earnings (EBITDA): 1.36B vs. JAZZ (372M). INCY has more cash in the bank: 2.42B vs. JAZZ (1.67B). INCY has less debt than JAZZ: INCY (42.4M) vs JAZZ (5.43B). INCY has higher revenues than JAZZ: INCY (4.59B) vs JAZZ (4.09B).
INCYJAZZINCY / JAZZ
Capitalization16.2B7.6B213%
EBITDA1.36B372M364%
Gain YTD20.3711.6811,212%
P/E Ratio19.6515.38128%
Revenue4.59B4.09B112%
Total Cash2.42B1.67B145%
Total Debt42.4M5.43B1%
FUNDAMENTALS RATINGS
INCY vs JAZZ: Fundamental Ratings
INCY
JAZZ
OUTLOOK RATING
1..100
7519
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
3995
PRICE GROWTH RATING
1..100
4649
P/E GROWTH RATING
1..100
10073
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INCY's Valuation (59) in the Biotechnology industry is in the same range as JAZZ (70) in the Pharmaceuticals Other industry. This means that INCY’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's Profit vs Risk Rating (96) in the Pharmaceuticals Other industry is in the same range as INCY (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to INCY’s over the last 12 months.

INCY's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for JAZZ (95) in the Pharmaceuticals Other industry. This means that INCY’s stock grew somewhat faster than JAZZ’s over the last 12 months.

INCY's Price Growth Rating (46) in the Biotechnology industry is in the same range as JAZZ (49) in the Pharmaceuticals Other industry. This means that INCY’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's P/E Growth Rating (73) in the Pharmaceuticals Other industry is in the same range as INCY (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYJAZZ
RSI
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
62%
Bullish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
62%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
56%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
60%
Bullish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 14 days ago
61%
Bullish Trend 9 days ago
59%
Declines
ODDS (%)
Bearish Trend 5 days ago
58%
Bearish Trend 1 day ago
57%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
63%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
INCY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RMM13.920.10
+0.73%
RiverNorth Managed Duration Municipal Income Fund
RVRB34.680.19
+0.54%
Reverb ETF
VEGA48.290.08
+0.17%
AdvisorShares STAR Global Buy-Write ETF
CBOA26.680.01
+0.04%
Calamos Bitcoin Structured Alt Protection ETF - April
SOXS6.16-0.15
-2.38%
Direxion Daily Semicondct Bear 3X ETF

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with TECH. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then TECH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+0.05%
TECH - INCY
42%
Loosely correlated
+0.70%
AXON - INCY
39%
Loosely correlated
+0.62%
REGN - INCY
38%
Loosely correlated
+2.25%
LGND - INCY
37%
Loosely correlated
-0.14%
SYRE - INCY
37%
Loosely correlated
-5.18%
More